Immune Thrombocytopenia
Conditions
Keywords
immune thrombocytopenia
Brief summary
The purpose of this study was to observe the clinical efficacy and adverse reactions of rhTPO in the treatment of pregnancy-induced thrombocytopenia.
Detailed description
The project is undertaken by Qilu Hospital of Shandong University and other 6 well-known hospitals in China. The investigators anticipate to undertaking a concurrent control, multicentre trial including 60 pregnancy associated ITP adult patients which are ineffective for first-line treatment or platelets infusion and 30 healthy pregnancy control. 30 of the ITP patients are selected to receive rhTPO(given different dose according to the platelet count, the risk of bleeding and delivery), the other ITP patients are selected not to receive rhTPO. Platelet count, bleeding and other symptoms of ITP patients and their newborns are evaluated after treatment, adverse events are also recorded throughout the study in order to report the efficacy and safety of the rhTPO for the treatment of pregnancy with ITP.
Interventions
If platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
according to the their conditions, use if necessary
Sponsors
Peking University People's Hospital
First Affiliated Hospital of Chongqing Medical University
Linyi People's Hospital
The Affiliated Hospital of Qingdao University
Shandong Provincial Hospital
Zhongshan Bo Ai Hospital
Shandong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Meet the diagnostic criteria for immune thrombocytopenia. 2. 18-50 years of age; gestational age over 32 weeks; 3. No response to the treatment of glucocorticoids and / or intravenous immunoglobulin (a stable dose of glucocorticoid could be accepted); 4. Platelet transfusion was not effective. 5. Platlet count of the patients \<30\* 10\^9/L and had the risk of bleeding or bleeding. 6. No obvious abnormalities in liver and kidney function had (1.5 times higher than normal limit of the serum urea nitrogen, creatinine, serum transaminase and bilirubin ); 7. No severe cardiac and pulmonary dysfunction; 8. No history of mental illness; 9. Voluntarily signed written informed consent.
Exclusion criteria
1. A history of serious allergies to biologics; 2. The history of thrombosis; 3. Thromboembolic or hemorrhagic disease; 4. Patients who are deemed unsuitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet count during delivery | up to 2 years per subject | Platelet count during delivery will be assessed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events in neonates | up to 2 years per subject | The number and frequency of therapy associated adverse events in neonates |
| platlet count of newborns | up to 42 days per newborn | Platelet counts of D1, 3, and 7 of newborns, extended to d42 if thrombocytopenia occurs. |
| Adverse events in parturients | up to 2 years per subject | The number and frequency of therapy associated adverse events in parturients |
Countries
China
Contacts
Primary ContactMing Hou, Dr
Outcome results
None listed